Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Employee Stories
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
News
Year
2021
2022
2023
2024
2025
Month
1
2
3
4
5
6
7
8
9
10
11
12
2025.04.30
Boan Biotech Presents Early Research Findings about Its Innovative Anti-CD25 Antibody (BA1106) at AACR Annual Meeting 2025
2025.04.22
Phase 3 Trial Results of Boan Biotech’s Dulagutide Injection Published in Journal of Diabetes
2025.03.28
Boan Biotech Announces 2024 Financial Results
27
2025-03
Boan Biotech's CD228 ADC Granted ODD by US FDA
20
2025-03
Boan Holds BPD Type 2b Meeting with FDA on BA1104
17
2025-02
Phase 3 Trial Results of Boan Biotech’s BA1102 (Denosumab Injection) Published in Journal of Bone Oncology
23
2024-12
Boan published a review of potential solid tumor target CD228
26
2024-11
Boan Reached a Strategic Cooperation for Denosumab in Brazil
19
2024-11
First Patient Dosed in Phase 1 Study of Boan’s CD228 ADC
24
2024-10
Boan’s site-specific Integration Cell Line Development Platform BA-Fastcell® Debuted at BPI Asia 2024
1
2
3
4
5
Follow me
鲁公网安备37069102000284
ICP备：鲁ICP备2021004064号-1
